ONM-421 / OncoNano Medicine - LARVOL DELTA

ONM-421, a pH-responsive polymer-drug conjugate nanoparticle, delivers MMAE to solid tumors and shows antigen-independent antitumor efficacy in mice (AACR 2026) - "Efficacy and tolerability of ONM-421 was studied in vivo in multiple human xenograft models, HT-29, HCT-116, and FaDu compared to docetaxel (DTX) and a tissue factor targeting MMAE-ADC tisotumab vedotin (TV). ONM-421 showed stable uniformly distributed size (Dh<50nm), <1% free MMAE, and consistent pH-responsiveness over a 6-month ongoing storage stability study. ONM-421 demonstrated potent antigen-independent antitumor efficacy in multiple xenograft tumors with good tolerability in mice. The data justifies further development of ONM-421 towards IND-enabling studies."

Preclinical • Oncology • Solid Tumor • CTSB

OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD Platform (Businesswire) - "Preclinical data show strong in vitro and in vivo anti-tumor activity across a range of payload-linker combinations, including superior tumor growth inhibition and robust responses compared to standard-of-care agents....ONM-421 showed broader activity compared to an MMAE-based antibody-drug conjugate, including efficacy in tumors with low target expression where the ADC was less active. In these models, ONM-421 also demonstrated improved tolerability relative to a standard chemotherapy when given at an efficacious dose."

Preclinical • Solid Tumor